Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of the Safety, Efficacy, and Cell Pharmacokinetics of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

NCT07203404 is registered in ClinicalTrials.gov with Nanjing Bioheng Biotech Co., Ltd. as lead sponsor.

NCT NCT07203404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07203404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of the Safety, Efficacy, and Cell Pharmacokinetics of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Lead sponsor
Nanjing Bioheng Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 24, 2025
Completion date
July 23, 2028
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, anca-associated glomerulonephritis, anti-gbm disease, iga nephropathy, iim, ln, mn, sle, ssc